Candel Therapeutics' Aglatimagene Shows Prolonged Survival in NSCLC…

Event summary

Candel Therapeutics published Phase 2a trial data showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors (ICI).
The trial enrolled 46 evaluable patients, with 37% of those with progressive disease on ICI surviving beyond 24 months.
Non-squamous NSCLC patients showed even more pronounced benefits, with a median overall survival of 25.4 months.
Aglatimagene plus valacyclovir demonstrated systemic immune activation and was generally well-tolerated.
The company is advancing to a global Phase 3 AURORA trial evaluating aglatimagene in metastatic non-squamous NSCLC.

The big picture

Candel Therapeutics' positive Phase 2a trial results for aglatimagene besadenovec plus valacyclovir represent a significant advancement in treating advanced NSCLC patients who have failed immune checkpoint inhibitors. The data suggests a potential paradigm shift in oncology, particularly for patients with limited treatment options. The company's ability to secure regulatory approval and commercialize this therapy will be closely watched, as it could set a new standard for immunotherapy in NSCLC.

What we're watching

Clinical Validation: Whether the Phase 2a results will translate into successful outcomes in the Phase 3 AURORA trial, which is critical for regulatory approval and commercialization.
Market Differentiation: How Candel Therapeutics positions aglatimagene against existing treatments for NSCLC, particularly in the checkpoint-refractory patient population.
Regulatory Pathway: The pace at which the FDA and other regulatory bodies will review and potentially approve aglatimagene, given its Fast Track and Orphan Drug Designations.